Evolutions in fragment-based drug design: The deconstruction-reconstruction approach

Haijun Chen, Xiaobin Zhou, Ailan Wang, Yunquan Zheng, Yu Gao, Jia Zhou

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Recent advances in the understanding of molecular recognition and protein-ligand interactions have facilitated rapid development of potent and selective ligands for therapeutically relevant targets. Over the past two decades, a variety of useful approaches and emerging techniques have been developed to promote the identification and optimization of leads that have high potential for generating new therapeutic agents. Intriguingly, the innovation of a fragment-based drug design (FBDD) approach has enabled rapid and efficient progress in drug discovery. In this critical review, we focus on the construction of fragment libraries and the advantages and disadvantages of various fragment-based screening (FBS) for constructing such libraries. We also highlight the deconstruction-reconstruction strategy by utilizing privileged fragments of reported ligands.

Original languageEnglish (US)
Pages (from-to)105-113
Number of pages9
JournalDrug Discovery Today
Volume20
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Drug Design
Ligands
Drug Discovery
Libraries
Proteins
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Evolutions in fragment-based drug design : The deconstruction-reconstruction approach. / Chen, Haijun; Zhou, Xiaobin; Wang, Ailan; Zheng, Yunquan; Gao, Yu; Zhou, Jia.

In: Drug Discovery Today, Vol. 20, No. 1, 2015, p. 105-113.

Research output: Contribution to journalArticle

Chen, Haijun ; Zhou, Xiaobin ; Wang, Ailan ; Zheng, Yunquan ; Gao, Yu ; Zhou, Jia. / Evolutions in fragment-based drug design : The deconstruction-reconstruction approach. In: Drug Discovery Today. 2015 ; Vol. 20, No. 1. pp. 105-113.
@article{5f071719288d4304af584e299d6c556e,
title = "Evolutions in fragment-based drug design: The deconstruction-reconstruction approach",
abstract = "Recent advances in the understanding of molecular recognition and protein-ligand interactions have facilitated rapid development of potent and selective ligands for therapeutically relevant targets. Over the past two decades, a variety of useful approaches and emerging techniques have been developed to promote the identification and optimization of leads that have high potential for generating new therapeutic agents. Intriguingly, the innovation of a fragment-based drug design (FBDD) approach has enabled rapid and efficient progress in drug discovery. In this critical review, we focus on the construction of fragment libraries and the advantages and disadvantages of various fragment-based screening (FBS) for constructing such libraries. We also highlight the deconstruction-reconstruction strategy by utilizing privileged fragments of reported ligands.",
author = "Haijun Chen and Xiaobin Zhou and Ailan Wang and Yunquan Zheng and Yu Gao and Jia Zhou",
year = "2015",
doi = "10.1016/j.drudis.2014.09.015",
language = "English (US)",
volume = "20",
pages = "105--113",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Evolutions in fragment-based drug design

T2 - The deconstruction-reconstruction approach

AU - Chen, Haijun

AU - Zhou, Xiaobin

AU - Wang, Ailan

AU - Zheng, Yunquan

AU - Gao, Yu

AU - Zhou, Jia

PY - 2015

Y1 - 2015

N2 - Recent advances in the understanding of molecular recognition and protein-ligand interactions have facilitated rapid development of potent and selective ligands for therapeutically relevant targets. Over the past two decades, a variety of useful approaches and emerging techniques have been developed to promote the identification and optimization of leads that have high potential for generating new therapeutic agents. Intriguingly, the innovation of a fragment-based drug design (FBDD) approach has enabled rapid and efficient progress in drug discovery. In this critical review, we focus on the construction of fragment libraries and the advantages and disadvantages of various fragment-based screening (FBS) for constructing such libraries. We also highlight the deconstruction-reconstruction strategy by utilizing privileged fragments of reported ligands.

AB - Recent advances in the understanding of molecular recognition and protein-ligand interactions have facilitated rapid development of potent and selective ligands for therapeutically relevant targets. Over the past two decades, a variety of useful approaches and emerging techniques have been developed to promote the identification and optimization of leads that have high potential for generating new therapeutic agents. Intriguingly, the innovation of a fragment-based drug design (FBDD) approach has enabled rapid and efficient progress in drug discovery. In this critical review, we focus on the construction of fragment libraries and the advantages and disadvantages of various fragment-based screening (FBS) for constructing such libraries. We also highlight the deconstruction-reconstruction strategy by utilizing privileged fragments of reported ligands.

UR - http://www.scopus.com/inward/record.url?scp=84921533887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921533887&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2014.09.015

DO - 10.1016/j.drudis.2014.09.015

M3 - Article

C2 - 25263697

AN - SCOPUS:84921533887

VL - 20

SP - 105

EP - 113

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 1

ER -